Blackstone and TPG completed their acquisition of Hologic, moving the molecular diagnostics and medical technology company to the private markets. The deal, valued at up to $18.3 billion, takes Hologic private and will end its Nasdaq trading. The transaction provides shareholders $76 per share in cash plus a non-tradeable contingent value right worth up to $3 per share based on achieving global revenue goals in fiscal years 2026 and 2027. José Almeida, most recently CEO of Baxter International, was named CEO effective immediately. Hologic’s move reflects ongoing private-market appetite for diagnostics assets and the strategic shift toward accelerating growth without the compliance constraints associated with public-market reporting.